Abstract: A method according to one embodiment includes receiving baseline health data of a user, receiving activity-based health data of the user collected by a sensor device worn by the user while participating in physical activity, and receiving environmental-based data of the user. A baseline core body temperature of the user is calculated. It is determined whether a core body temperature of the user has increased a predetermined amount from the baseline core body temperature of the user for a predetermined amount of time during each of a predetermined number of time intervals. In response to a determination that the core body temperature has increased the predetermined amount from the baseline core body temperature of the user for the predetermined amount of time during each of the predetermined number of time intervals, a personalized schedule is generated for the user to follow while participating in the physical activity.

Abstract: A method according to one embodiment includes determining whether a user has successfully heat acclimatized to a predetermined environment. Subsequent to a determination that the user has successfully heat acclimatized, it is determined whether the user has heat de-acclimatized to the predetermined environment. In response to a determination that the user has heat de-acclimatized, a predetermined process is performed. The predetermined process includes determining whether the user has successfully heat re-acclimatized to the predetermined environment.

Abstract: A method according to one embodiment includes receiving baseline health data of a user, receiving activity-based health data of a user collected by a sensor device worn by the user while participating in physical activity, and receiving environmental-based data of the user collected by the sensor device worn by the user and/or from an external application programming interface (API). A personalized schedule is generated for the user to follow while participating in the physical activity based on the baseline health data of the user, the activity-based health data of the user and the environmental-based data of the user. The personalized schedule includes at least one instruction of an amount of fluids for the user to consume while participating in the physical activity to maintain hydration of the user and prevent dehydration of the user. The method further includes outputting the personalized schedule for display on the user device.

Abstract: A method according to one embodiment includes receiving baseline health data of a user, receiving activity-based health data of the user collected by a sensor device worn by the user while participating in physical activity and receiving environmental-based data of the user collected by the sensor device worn by the user. An alert is output for display on a user device in response to a determination that a core body temperature of the user is greater than a predetermined threshold temperature. A personalized schedule is generated for the user to follow while participating in the physical activity. The personalized schedule includes at least one instruction of when to start participating in the physical activity and at least one instruction of when to stop participating in the physical activity. The method further includes outputting the personalized schedule for display on the user device.

Abstract: A method according to one embodiment includes receiving baseline health data of a user, receiving activity-based health data of a user collected by a sensor device worn by the user while participating in physical activity and receiving environmental-based data of the user. A personalized heat risk level alert is generated and includes a personalized heat risk level stratification of the user. The personalized heat risk level alert is output for display on a user device. The method further includes generating a guided activity plan for the user to participate in for a predetermined amount of time while wearing the sensor device, and outputting the guided activity plan for display on the user device. Second activity-based health data of the user collected by the sensor device worn by the user while participating in the guided activity plan is received and a heat tolerance alert is generated.

Abstract: The object of the invention are compositions and medical treatment methods with an inheritable, Gram-negative, strictly anaerobic and commensal bacterium of the family Christensenellaceae belonging to an OTU (Operational Taxonomic Unit) characterized by a 16S rRNA sequence SEQ ID NO: 1 or to an OTU characterized by a 16S rRNA sequence SEQ ID NO: 2.

Abstract: The object of the invention are compositions and medical treatment methods with an inheritable, Gram-negative, strictly anaerobic and commensal bacterium of the family Christensenellaceae belonging to an OTU (Operational Taxonomic Unit) characterized by a 16S rRNA sequence SEQ ID NO: 1 or to an OTU characterized by a16S rRNA sequence SEQ ID NO: 2.

Abstract: The object of the invention are compositions and medical treatment methods with an inheritable, Gram-negative, strictly anaerobic and commensal bacterium of the family Christensenellaceae belonging to an OTU (Operational Taxonomic Unit) characterized by a 16S rRNA sequence SEQ ID NO: 1 or to an OTU characterized by a 16S rRNA sequence SEQ ID NO: 2.

Abstract: A dietary product for preventing cardiometabolic risk in humans, in particular for reducing visceral fat and deep subcutaneous fat, includes in particular a mixture of: a whey hydrolysate having a molecular weight of between 200 and 10,000 daltons, an isolate and/or concentrate of whey, and calcium caseinate.

Abstract: The object of the invention are compositions and medical treatment methods with an inheritable, Gram-negative, strictly anaerobic and commensal bacterium of the family Christensenellaceae belonging to an OTU (Operational Taxonomic Unit) characterized by a 16S rRNA sequence SEQ ID NO: 1 or to an OTU characterized by a 16S rRNA sequence SEQ ID NO: 2.

Abstract: The object of the invention are compositions and medical treatment methods with an inheritable, Gram-negative, strictly anaerobic and commensal bacterium of the family Christensenellaceae belonging to an OTU (Operational Taxonomic Unit) characterized by a 16S rRNA sequence SEQ ID NO: 1 or to an OTU characterized by a165 rRNA sequence SEQ ID NO: 2.

Abstract: The invention relates to the use as a drug or medical nutritional product in humans to treat a pathological dysbiosis and/or to prevent or treat at least one derived metabolic disease chosen from among excess weight with comorbidity, obesity, diabetes, heart and vascular diseases, atherosclerosis, degenerative bone disease, neurodegenerative disease, metabolism-related cancers, autoimmune diseases, steatosis, metabolic steatohepatitis, and chronic inflammatory diseases of the intestine, by increasing the Christensenella bacterial genus in the intestine, of a composition comprising a mixture of active ingredients consisting of at least: a whey hydrolysate with a molecular weight comprised between 200 and 10,000 Daltons, a whey isolate and/or a concentrate, and calcium caseinate.

Abstract: The invention relates to the use as a drug or medical nutritional product in humans to treat a pathological dysbiosis and/or to prevent or treat at least one derived metabolic disease chosen from among excess weight with comorbidity, obesity, diabetes, heart and vascular diseases, atherosclerosis, degenerative bone disease, neurodegenerative disease, metabolism-related cancers, autoimmune diseases, steatosis, metabolic steatohepatitis, and chronic inflammatory diseases of the intestine, by increasing the Christensenella bacterial genus in the intestine, of a composition comprising a mixture of active ingredients consisting of at least: a whey hydrolysate with a molecular weight comprised between 200 and 10,000 Daltons, a whey isolate and/or a concentrate, and calcium caseinate.

Abstract: The invention relates to the use as a drug or medical nutritional product in humans to treat a pathological dysbiosis and/or to prevent or treat at least one derived metabolic disease chosen from among excess weight with comorbidity, obesity, diabetes, heart and vascular diseases, atherosclerosis, degenerative bone disease, neurodegenerative disease, metabolism-related cancers, autoimmune diseases, steatosis, metabolic steatohepatitis, and chronic inflammatory diseases of the intestine, by increasing the Christensenella bacterial genus in the intestine, of a composition comprising a mixture of active ingredients consisting of at least: a whey hydrolysate with a molecular weight comprised between 200 and 10,000 Daltons, a whey isolate and/or a concentrate, and calcium caseinate.

Abstract: A composition suitable for use as a health product, including a mixture of active ingredients made up of at least: a lactoserum hydrolysate with a molecular weight between 200 and 5000 daltons, alpha-lactalbumin, at least one AMPK, MAPK, PPAR and/or SIRT1 cycle regulator, and milk calcium. The composition is particularly useful as a medical nutrition product or orally administered drug, to prevent and/or combat various diseases.

Abstract: The invention relates to the use as a drug or medical nutritional product in humans to treat a pathological dysbiosis and/or to prevent or treat at least one derived metabolic disease chosen from among excess weight with comorbidity, obesity, diabetes, heart and vascular diseases, atherosclerosis, degenerative bone disease, neurodegenerative disease, metabolism-related cancers, autoimmune diseases, steatosis, metabolic steatohepatitis, and chronic inflammatory diseases of the intestine, by increasing the Christensenella bacterial genus in the intestine, of a composition comprising a mixture of active ingredients consisting of at least: a whey hydrolysate with a molecular weight comprised between 200 and 10,000 Daltons, a whey isolate and/or a concentrate, and calcium caseinate.

Abstract: The invention relates to an orally administered drug or medical nutrition composition for use in the prevention or treatment of metabolic steatosis and steatohepatitis of abdominally obese people with metabolic syndrome. The composition comprises at least: proteins and/or free amino adds, fibers selected at least from acacia gum fibers and/or fructooligosaccharide fibers, vitamins D, B6, B9, B12 and E, omega 3 in the form of ALA, glutathione, SOD, catalase, choline.

Abstract: A composition for oral administration in humans comprising at least one plant protein chosen from pea proteins, rice proteins or a mixture thereof, and: at least one protein of animal origin chosen from calcium caseinate, lactoserum proteins, or a mixture thereof, and/or at least one free amino acid chosen from leucine, glutamine, isoleucine, valine, tryptophan or plant 5HTP, lysine, threonine, arginine and taurine, or any mixture thereof, and/or at least one micronutrient chosen from vitamin D, vitamin B6, vitamin B9, vitamin E, milk calcium, marine magnesium, zinc and chromium, or any mixture thereof, and/or at least one anti-inflammatory and/or antioxidant compound of plant origin chosen from ALA omega-3 fatty acid, purified EPA, protectin in PD1 or PDX form, and curcumin, or any mixture thereof. Methods with these compositions for preventing cardiometabolic risk are also provided.

Abstract: An orally administered dietary product intended to reduce an obese person's visceral fat during the pre-operative phase prior to bariatric surgery, the product includes in particular a mixture of: a whey hydrolysate having a molecular weight of between 200 and 10,000 daltons, an isolate and/or a concentrate of whey, and calcium caseinate.

Abstract: An orally administered dietary product intended to reduce an obese person's visceral fat during the pre-operative phase prior to bariatric surgery, the product includes in particular a mixture of: a whey hydrolysate having a molecular weight of between 200 and 10,000 daltons, an isolate and/or a concentrate of whey, and calcium caseinate.